Announcements Trials
Browse Landscape

Phase

Phase 2 221Phase 1 123Phase 3 52Phase 1/2 48Phase NA 6Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 2

Status

Not yet recruiting 2Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Bortezomib × Clear all
NCT00861250 2016-06-17

Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

Tampere University Hospital

Phase 2/3 Completed
47 enrolled
Plasma cell

Multiple Myeloma

NCT00514371 2015-12-07

TIME-2

Bristol-Myers Squibb

Phase 2/3 Completed
22 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡